BeyondSpring Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $47,791,000 compared with $1,915,000 for the same period a year ago. Loss before income tax was $47,712,000 compared with $1,909,000 for the same period a year ago. Net loss attributable to BeyondSpring Inc. was $47,396,000 or $2.66 per basic and diluted share compared with $1,844,000 or $0.12 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $5,279,000 compared with $1,991,000 for the same period a year ago. Acquisitions of property and equipment was $14,000. This increase in net loss was primarily due to increased research and development costs. The increased research and development costs mainly related to continuing Phase 3 clinical trial of Plinabulin in combination with docetaxel for patients with advanced NSCLC who have measurable lung lesions, and preparations to start registrational clinical program of Plinabulin to prevent chemotherapy-induced neutropenia.